Gentian Diagnostics ASA
OSE:GENT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
35.8
59
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GENT stock under the Base Case scenario is 34.32 NOK. Compared to the current market price of 41 NOK, Gentian Diagnostics ASA is Overvalued by 16%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Gentian Diagnostics ASA
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
Valuation History
Historical valuation for GENT cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Gentian Diagnostics ASA
Balance Sheet Decomposition
Gentian Diagnostics ASA
Current Assets | 147.5m |
Cash & Short-Term Investments | 93.8m |
Receivables | 11.1m |
Other Current Assets | 42.6m |
Non-Current Assets | 41.6m |
Long-Term Investments | 104k |
PP&E | 15.4m |
Intangibles | 26m |
Other Non-Current Assets | -1k |
Current Liabilities | 21m |
Other Current Liabilities | 21m |
Non-Current Liabilities | 6.7m |
Long-Term Debt | 6.6m |
Other Non-Current Liabilities | 75k |
Earnings Waterfall
Gentian Diagnostics ASA
Revenue
|
146.9m
NOK
|
Cost of Revenue
|
-71m
NOK
|
Gross Profit
|
75.9m
NOK
|
Operating Expenses
|
-76m
NOK
|
Operating Income
|
-41k
NOK
|
Other Expenses
|
2.3m
NOK
|
Net Income
|
2.2m
NOK
|
Free Cash Flow Analysis
Gentian Diagnostics ASA
NOK | |
Free Cash Flow | NOK |
GENT Profitability Score
Profitability Due Diligence
Gentian Diagnostics ASA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Gentian Diagnostics ASA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
GENT Solvency Score
Solvency Due Diligence
Gentian Diagnostics ASA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Gentian Diagnostics ASA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GENT Price Targets Summary
Gentian Diagnostics ASA
According to Wall Street analysts, the average 1-year price target for GENT is 68.34 NOK with a low forecast of 67.67 NOK and a high forecast of 70.35 NOK.
Dividends
Current shareholder yield for GENT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one GENT stock under the Base Case scenario is 34.32 NOK.
Compared to the current market price of 41 NOK, Gentian Diagnostics ASA is Overvalued by 16%.